Previous research demonstrated that the expression of EGFR was significantly increased in HPV‐negative HNSCC tumors, whereas the expression of HER2 and HER3 was significantly elevated in HPV‐positive HNSCC, suggesting that agents targeting multiple HER receptors might be more effective in HPV‐positive HNSCC (Mazibrada et al., 2014; Pollock et al., 2015). This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.